Publicacions en què col·labora amb Manuel Arrojo Romero (31)

2024

  1. Clustering Schizophrenia Genes by Their Temporal Expression Patterns Aids Functional Interpretation

    Schizophrenia Bulletin, Vol. 50, Núm. 2, pp. 327-338

2023

  1. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  2. Examining the association between exposome score for schizophrenia and cognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    Psychiatry Research, Vol. 323

  3. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

  4. Tobacco use in first-episode psychosis, a multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 15, pp. 7265-7276

2022

  1. A polygenic approach to the association between smoking and schizophrenia

    Addiction Biology, Vol. 27, Núm. 1

  2. A replication study of JTC bias, genetic liability for psychosis and delusional ideation

    Psychological Medicine, Vol. 52, Núm. 9, pp. 1777-1783

  3. Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway

    Psychological Medicine, Vol. 52, Núm. 10, pp. 1910-1922

  4. Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 113

  5. The association between cannabis use and facial emotion recognition in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    European Neuropsychopharmacology, Vol. 63, pp. 47-59

2021

  1. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

    Molecular Psychiatry, Vol. 26, Núm. 8, pp. 4529-4543

  2. Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study

    European psychiatry : the journal of the Association of European Psychiatrists, Vol. 64, Núm. 1, pp. e25

  3. Spanish validation of the Empirically Developed Clinical Staging Model (EmDe-5) for patients with bipolar disorder

    Revista de Psiquiatria y Salud Mental

  4. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

    Translational Psychiatry, Vol. 11, Núm. 1

2020

  1. Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum

    Epidemiology and Psychiatric Sciences

  2. Premorbid Adjustment and IQ in Patients with First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship with Cannabis Use

    Schizophrenia Bulletin, Vol. 46, Núm. 3, pp. 517-529

  3. Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study

    Psychological Medicine, Vol. 50, Núm. 11, pp. 1884-1897

  4. The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI): Incidence and First-Episode Case–Control Programme

    Social Psychiatry and Psychiatric Epidemiology, Vol. 55, Núm. 5, pp. 645-657

2019

  1. Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study

    Schizophrenia bulletin, Vol. 45, Núm. 5, pp. 960-965

  2. Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study

    World Psychiatry, Vol. 18, Núm. 2, pp. 173-182